Toshiba launches trial to compare 320-detector row CT to SPECT
Toshiba Medical Systems will support CorE 320, an international multi-center trial, beginning this month, to compare the effectiveness of 320-detector row dynamic volume CT to SPECT technology in identifying coronary stenosis.
The trial will examine whether the combination of CT angiography and myocardial perfusion can identify coronary stenoses that are less than or equal to 50 percent by quantitative coronary analysis, and correspond to a SPECT perfusion defect. Toshiba said that the Aquilion One, a volume CT system, will be used.
The CorE 320 trial will be lead by primary investigator João A. C. Lima, MD, of Johns Hopkins University School of Medicine, in Baltimore. Johns Hopkins University will also serve as the core site for CT. Marcelo Di Carli, MD, of Brigham and Women’s Hospital in Boston will serve as core site for SPECT.
The Tustin, Calif.-based company said that additional investigation sites will be announced in the coming months.
The trial will examine whether the combination of CT angiography and myocardial perfusion can identify coronary stenoses that are less than or equal to 50 percent by quantitative coronary analysis, and correspond to a SPECT perfusion defect. Toshiba said that the Aquilion One, a volume CT system, will be used.
The CorE 320 trial will be lead by primary investigator João A. C. Lima, MD, of Johns Hopkins University School of Medicine, in Baltimore. Johns Hopkins University will also serve as the core site for CT. Marcelo Di Carli, MD, of Brigham and Women’s Hospital in Boston will serve as core site for SPECT.
The Tustin, Calif.-based company said that additional investigation sites will be announced in the coming months.